Prevention of medication related osteonecrosis of the jaw after dentoalveolar surgery: An institution’s experience

Onur Şahin¹, Birkan Tatar¹, Ceren Ekmekcioğlu¹, Toghrul Aliyev¹, Onur Odabaşı²

¹ Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, İzmir Katip Çelebi University, İzmir, Türkiye
² Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Ankara Yıldırım Beyazıt University Ankara, Türkiye

Correspondence:
Department of Oral and Maxillofacial Surgery
Faculty of Dentistry, İzmir Katip Çelebi University
İzmir, Turkey
Aydınlıkevler Mah. 6782 Sok
No: 48 35640 Çiğli/ İzmir/ Türkiye
onursahin43@hotmail.com

Received: 28/01/2020
Accepted: 14/05/2020

Abstract
Background: Dentoalveolar surgery is a predisposing factor for medication related osteonecrosis of the jaw (MRONJ). The aim of our study was to evaluate the described surgical procedures to prevent the development of MRONJ after dentoalveolar surgery in patients receiving bisphosphonates.

Material and Methods: In this retrospective study, sixty-three dentoalveolar surgeries were performed on 44 patients taking bisphosphonate in accordance with the treatment procedures we described. The following procedures were applied to patients 1) use of antibiotics 2) performed dentoalveolar surgical procedures 3) fill the socket with leukocyte- and platelet-rich fibrin (L-PRF) 4) post-operative application of low level laser therapy through Nd: YAG laser 5) sutures were removed on post-op 14th day 6) long-term results were evaluated.

Results: Healing of all patients was uneventful. Complete mucosal healing was achieved in all patients at 1 month. There is no failure was observed in long-term follow-up.

Conclusions: Because of the pathophysiology of MRONJ is not fully understood and has many risk factors, definitive protocols on prevention and treatment have not been established yet. Personal risk assessment is required for the prevention and treatment of MRONJ. The described surgical protocol may be considered to reduce the risk of developing MRONJ after dentoalveolar surgery due to its high success rate.

Key words: Tooth extraction, medication related osteonecrosis of the jaw, preventive dentistry, L-PRF, low level laser therapy.

Introduction
Bisphosphonates (BPs) are the most commonly used antiresorptive drugs to prevent skeletal complications of many diseases (1). It is used to reduce serious complications such as hypercalcemia and pathological fractures, as well as to improve the quality of life and reduce pain complaints of cancer patients with bone metastases (2). One of the most important side effects of BPs is that it causes osteonecrosis in the jaw bones. Increased cases of osteonecrosis localized in the jaw bones related to
BPs and antiresorptive drugs, negative impact on quality of life and increased morbidity led researchers to define early MRONJ and to investigate effective treatment modality. Although many studies have been conducted on the mechanism of action of bisphosphonates, its pathophysiology remains unclear. Bisphosphonates accumulate highly in bones and adjacent soft tissues with high turnover rates. Therefore, it is thought that if mucosal integrity is deteriorated, endothelial cell prophylaxis and wound healing delay and secondary infections occur in exposed mandible and maxilla, and later become osteonecrosis (3).

Several factors such as therapeutic indication, drug type and duration, local, demographic, systemic and genetic factors have been mentioned in determining the incidence of MRONJ (4). Local etiologic factors that are effective in the development of MRONJ are defined as dentoalveolar surgical procedures, anatomical factors, prosthesis and associated local oral inflammatory diseases. A large review by Filleul et al. (5) concluded that tooth extraction was the main triggering factor in 67% of MRONJ cases. Tooth extraction alone is a predisposing factor in MRONJ formation between 52% and 61% (6). The incidence of osteonecrosis after tooth extraction is reported to be 0.5% in patients using BPs, whereas it is reported to be between 1.6% and 14.8% in patients using BPs intravenously (7). These studies show that tooth extraction is an important risk factor for MRONJ formation. Therefore, various procedures have been determined to prevent the occurrence of osteonecrosis after tooth extraction. Studies include methods such as drug discontinuation, improved oral hygiene, antibiotic and mouthwash treatment, atraumatic extraction, primary closure of the extraction socket, laser biostimulation and use of autologous platelet concentrates (8,9).

The aim of our study was to evaluate the described surgical procedures to prevent the development of MRONJ after dentoalveolar surgery in patients receiving bisphosphonate therapy.

**Material and Methods**

This retrospective study included 44 patients (32 females, 12 males) who received bisphosphonate and antiresorptive drug therapy and required dentoalveolar surgery between 2017 May–2019 May. The study was approved by the ethical committee of our university (Katip Çelebi University Non-Interventional Clinical Studies Institutional Review Board, Türkiye, No:311). All authors read the Helsinki Declaration and followed the guidelines in the study. Informed consent was obtained from all participants.

The study included patients who were received bisphosphonates for osteoporosis or oncologic purposes requiring dentoalveolar surgery. Patients with a history of radiotherapy, a history of metastasis localized to the jawbone and with MRONJ of the extraction site were excluded from the study.

**Procedure**

The following procedures were applied to patients who referred to our department for dentoalveolar surgery.

1. Demographic data, systemic diseases, history of bisphosphonate treatment (type of drug, route of use, duration of use), smoking habit, diabetes, steroid use were recorded at the first visit.

2. Clinical and radiological evaluation were performed to confirm the absence of MRONJ.

3. Patients continued to take medication.

4. 1000 mg of amoxicillin / clavulanic acid, 500 mg of metronidazole and 0.12% chlorhexidine digluconate mouthwash were prescribed for use 3 days before surgery and for 2 weeks post-op.

5. Surgical procedures were performed under local anesthesia (2 ml of 4% articaine hydrochloride with 1:200,000 epinephrine). Intraligamental and intrapapillary anesthesia was not applied due not to prevent the recovery.

6. Only the sulcular incision was used in the extraction of the teeth with mucosal retention.

7. After the tooth extraction, the sharp bone edges were rounded with burs.

8. After the extraction, venous blood obtained from the patient’s peripheral blood was centrifuged at 3000 rpm for 10 minutes in 10 ml tubes without anticoagulant and obtained L-PRF placed into the extraction socket by figure-of-eight sutures. No releasing vertical incisions or mucoperiosteal incisions were made for the primary closure.

9. Nd: YAG laser (Fotona-Slovenia) was used for biostimulation (wavelength 1064 nm, power 1.25 W, frequency 15Hz, fiere 320 μmin diameter) on post-operative Day 2, 5, 7, 10, 14, 21 and 28 defocalised at 1-2 mm from the tissue for 1 min repeated 5 times.

10. Sutures were removed on post-op 14th day.

11. Patients using prosthesis discontinued to use their prosthesis for 3 months and then used with soft lining material.

12. Patients were examined clinically and radiologically at post op 1, 3 and 6 months. Figure 1 showed the surgical procedures for one of the patients. The results were evaluated for wound healing. Treatment was considered successful when complete mucosal healing was achieved in the surgical field at the 1st and 3rd month controls without fistula or exposed bone symptoms. Data were collected retrospectively from patient records and surgical documents. For statistical analysis, group means and standard deviations were calculated for each variable (age, gender, indication for BP, BP treatment duration and interval, BP type, route of drug administration, extraction site, treatment outcome and time of follow-up) by use of SPSS 21.0 (Statistical Package for
the Social Sciences, Chicago, IL, USA). Chi-square test was used to calculate categorical variables and Student-t test was used to calculate quantitative variables. All data were evaluated at a significance level of $p < 0.05$.

**Results**
A total of 44 patients were included to the study. The subject group consisted of 32 females and 12 males and a mean age of 66.3. 44 patients underwent 63 dentoalveolar surgeries in accordance with the treatment procedures we described (Table 1). 21 of the patients were on medication for underlying malignant disease (14 patients had breast cancer, 6 patients had prostate cancer and 1 patient had nasopharynx cancer) and 23 patients were using medication for osteoporosis. 18 of the patients were on zoledronate, 8 patients were on ibandronate and 18 patients using alendronate. Mean duration of drug use via IV route: 44.6 months (25-108 months) and via oral route: 36.3 months (18-96 months). 23 of the dentoalveolar surgical sites were in the maxilla and 40 were in the mandible (Table 2). The response to treatment of each patient was recorded by regular controls. Healing of all patients was uneventful. Complete mucosal healing was achieved in all patients at 1 month (Fig. 1). The mean follow-up was 14.2 months (6-28 months). There was no significant difference between the each variable (age, gender, indication for BP, BP treatment duration and interval, BP type, extraction site) and in terms of healing time ($p > 0.05$).

**Discussion**
BPs use increases day by day in the treatment of osteoporosis and slows down the resorption process in the bone. It is also used effectively in the treatment of multiple myeloma and metastatic bone tumors to improve the quality of life of the patient (10). However, the most serious side effect of these drugs is the risk of causing osteonecrosis, especially in the jaws (11).

**Table 1**: Dentoalveolar procedures performed in a group of patients.

| Dentoalveolar Surgery                        | Upper Jaw | Mandible |
|----------------------------------------------|-----------|----------|
| A 2° to 3° grade mobility tooth extractions | 18        | 33       |
| Semi impacted third molars                   | -         | 4        |
| Residual roots                               | 2         | 1        |
| Destructive tooth decay involving the roots  | 3         | 2        |

![Image](https://example.com/image.png)
is evidence to support that the incidence of MRONJ has been reduced by half in patients with preventive precautions before starting BP treatment (12). However, due to the lack of evidence-based studies in patients receiving bisphosphonate or antiresorptive therapy, a protocol to prevent MRONJ has not been established and is limited to the clinical experience of the researchers alone (13). Therefore, the aim of this study was to define a procedure to reduce the risk of MRONJ and stimulate healing after tooth extraction and to evaluate its effectiveness. In the literature, drug discontinuation before surgical procedures are discussed. Drug discontinuation may be a procedure to reduce the risk of MRONJ in patients with osteoporosis who do not require an urgent tooth extraction and can be discontinued with bisphosphonate therapy (14). In contrast, Hasegawa et al. (15) reported in a multicenter study that short-term drug withdrawal had no significant effect on the incidence of MRONJ. In our study, drug discontinuation was not applied due to the systemic diseases of patients and the long half-life of bisphosphonates.

Local infections alter the pH within the lesion, which is thought to be an important factor in the pathogenesis of jawbone osteonecrosis (16). Teeth that are indicated for extraction due to residual roots, periodontitis, pericoronitis, excessive caries are a local factor of infection and a risk factor for MRONJ (17). In this study, local infection site were eliminated by extracting teeth or roots. Antibiotics and antiseptic mouthwashes were used for pre op 3 days and post op 2 weeks before sutures were taken to prevent bacterial contamination of the bone and the surgical site and the underlying bone. Sharp bone edges in the surgical site increase the risk of secondary perforation; this is supported by the finding that MRONJ develops in the areas where mucosal thinning occurs (18). Therefore, all sharp bone edges in the surgical site should be eliminated to minimize the risk of secondary perforation (8). Thin oral mucosa on the sharp bone edge can be damaged by traumatic irritation. For this reason, the sharp edges of the bones were rounded in our patients and it was recommended that patients who use prosthesis should not use their prosthesis for 3

| Table 2: Clinical characteristics of patients included in the study. |
|-----------------------------------------------|
| **Sex**                                      |
| Male                                         | 12 cases |
| Female                                       | 32 cases |
| **Mean age (years)**                         | 66.3 ±10.61 |
| **Systemic Disease**                         |
| Breast Cancer                                | 14 cases |
| Prostate Cancer                              | 6 cases |
| Nasopharynx Cancer                           | 1 case |
| Osteoporosis                                 | 23 cases |
| **Drug Type**                                |
| Zoledronate                                  | 18 cases |
| Ibandronate                                  | 8 cases |
| Alendronate                                  | 18 cases |
| **Route of Drug Administration**             |
| Intravenous                                  | 20 cases |
| Oral                                         | 24 cases |
| **Duration of drug therapy**                 |
| Intravenous                                  | 44 months (25-108 months) |
| Oral                                         | 36 months (18-96 months) |
| **Extraction site**                          |
| Upper Jaw                                    | 23 cases |
| Mandible                                     | 40 cases |
| **Other risk factors**                       |
| Smoking habit                                | 7 cases |
| Steroids                                     | 2 cases |
| Diabetes                                     | 9 cases |
months. Three months later, the prostheses were lined and the patients were followed up.

The mechanism of action of BPs in the extraction socket has been described as decreasing oral epithelial cell migration, increasing apoptosis, preventing oral mucosal wound healing and inhibition of osteoclastic activity (19). Hikita et al. (20) investigated the effects of biphosphonates on post-extraction socket healing in rats. Histological and morphometric data showed that inhibition of osteoclast activity delayed post-extraction alveolar healing in rats injected with bisphosphonate compared to control group rats. The first 7 days after dentoalveolar surgery appear to be the most critical period for the onset of inflammatory processes that prevent healing and induce osteonecrosis (21). Autologous platelet concentrates (APCs) contain many growth factors and immune system components to support the healing process. Several clinical studies have reported the possible benefits of APCs in the prevention and treatment of MRONJ (22). Scoletta et al. (23) and Mazzetto et al. (24) reported that they prevented the formation of osteonecrosis by placing plasma rich in growth factors (PRGF) in the socket and Asaka et al. (25) reported that they prevented the formation of osteonecrosis by placing PRF. PRF is a second generation platelet concentrate that regulates inflammation and stimulates chemotactic factors involved in the immune response. Unlike platelet rich plasma (PRP) and PRGF, it is a completely autogenous biomaterial obtained without adding any external substances (26).

In this study, we applied L-PRF to the extraction sockets simultaneously with tooth extraction in patients at risk of MRONJ. Osteonecrosis was not encountered in any of our patients during short and long term follow-up. Previous studies have highlighted the importance of primary closure of extraction sockets. Vertical incisions or mucoperiosteal incisions were not performed to prevent pain and edema. The wound edges were sutured with figure-of-eight sutures. The effects of low-level laser therapy (LLLT) on wound healing have been reported in vitro and in vivo studies as faster epithelialization with decreased inflammation and increased collagen and granulation tissue (27). In 2011, Kan et al. (28) reported that they used laser therapy to prevent BRONJ after tooth extraction. Vescovi et al. reported that they prevented BRONJ after tooth extraction in patients under BP treatment and in high-risk patients with a history of BRONJ, using a clinical protocol supported by Nd: YAG laser therapy in two separate studies (29,30). In our study, we used Nd: YAG laser for biostimulation in accordance with the protocol of Vescovi et al. (30).

Conclusions

Because the pathophysiology of MRONJ is not fully understood and has many risk factors, definitive protocols on prevention and treatment have not been established yet. Personal risk assessment is required for the prevention and treatment of MRONJ. The surgical protocol presented in this study shows promising results for MRONJ protection after dentoalveolar surgery. Although prospective studies with larger sample sizes are needed, we believe that our study will lead to better designed future studies.

References

1. Gutta R, Louis P. Bisphosphonates and osteonecrosis of the jaws: Science and rationale. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007;104:186-193.
2. Assael LA. Oral bisphosphonates as a cause of bisphosphonate-related osteonecrosis of the jaws: clinical findings, assessment of risks and preventive strategies. J Oral Maxillofac Surg. 2009;67:35-43.
3. Reid IR, Bolland MJ, Grey AB. Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity? Bone. 2007;41:318-20.
4. Şahin O, Odabaş O, Aliyev T, Tatar B. Risk factors of medication-related osteonecrosis of the jaw: a retrospective study in a Turkish subpopulation. J Korean Assoc Oral Maxillofac Surg. 2019;45:108-15.
5. Filleul E, Crompto E, Saulo-ste S. Bisphosphonate-induced osteonecrosis of the jaw: a review of 2,400 patient cases. J Cancer Res Clin Oncol. 2010;136:1117-24.
6. Otto S, Tröltzsch M, Jambrovic V, Panyu S, Probst F, Ristow O, et al. Tooth extraction in patients receiving oral or intravenous bisphosphonate administration: a trigger for BRONJ development? J Craniomaxillofac Surg. 2015;43:847-54.
7. Yamazaki T, Yamori M, Ishizaki T, Asai K, Goto K, Takahashi K, et al. Increased incidence of osteonecrosis of the jaw after tooth extraction in patients treated with bisphosphonates: a cohort study. Int J Oral Maxillofac Surg. 2012;41:1397-403.
8. Heufelder MJ, Hendricks J, Remmerbach T, Ferlich B, Hemprich A, Wilde F. Principles of oral surgery for prevention of bisphosphate-related osteonecrosis of the jaw. Oral Surg Oral Med Oral Pathol Oral Radiol 2014;117:e429-e435.
9. Montefusco V, Gay F, Spina F, Miceli R, Maniezzo M, Teresa Ambrosini M, et al. Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates. Leuk Lymphoma. 2008;49:2156-62.
10. Stresing V, Daubini F, Benzaid I, Mönköken H, Clezardin P. Bisphosphonates in cancer therapy. Cancer Lett. 2007;257:16-35.
11. Marx RE, Cillo JE Jr, Ulloa JJ. Oral bisphosphonate-induced osteonecrosis of the jaw: a growing epidemic. J Oral Maxillofac Surg. 2003;61:1115-7.
12. Bonacina R, Mariani U, Villa F, Villa A. Preventive strategies and clinical implications for bisphosphonate-related osteonecrosis of the jaw: a review of 282 patients. J Can Dent Assoc. 2011;77:b147.
13. Malden N, Beltes C, Lopes V. Dental extractions and bisphosphonate-related osteonecrosis of the jaw: the assessment, consent and management, a proposed algorithm. Br Dent J. 2009;206:93-8.
14. Marx RE, Cillo JE Jr, Ulloa JJ. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg. 2007;65:2397-410.
15. Hasegawa T, Hayashida S, Kondo E, Takeda Y, Miyamoto H, Kawaoaka Y, et al. Medication-related osteonecrosis of the jaw after tooth extraction in cancer patients: a multicenter retrospective study. Osteoporos Int. 2019;30:231-9.
16. Otto S, Pautke C, Opelz C, Westphal I, Schwager J, et al. Prevention of osteonecrosis of the jaw (MRONJ). J Craniomaxillofac Surg. 2015;43:290-3.
18. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg. 2004;62:527-34.

19. Landesberg R, Cozin M, Cremers S, Woo V, Kousteni S, Sinha S, et al. Inhibition of oral mucosal cell wound healing by bisphosphonates. J Oral Maxillofac Surg. 2008;66:839-47.

20. Hikita H, Miyazawa K, Tabuchi M, Kimura M, Goto S. Bisphosphonate administration prior to tooth extraction delays initial healing of the extraction socket in rats. J Bone Miner Metab. 2009;27:663-72.

21. Barba-Recreo P, Pardo DC, de Vera JL, Yébenes L, Burgueño M. Zoledronic acid - related osteonecrosis of the jaws. Experimental model with dental extractions in rats. J Craniomaxillofac Surg 2014;42:744-50.

22. Lopez-Jornet P, Sanchez Perez A, Amaral Mendes R, Tobias A. Medication-related osteonecrosis of the jaw: Is autologous platelet concentrate application effective for prevention and treatment? A systematic review. J Craniomaxillofac Surg. 2016;44:1067-72.

23. Scoletta M, Arata V, Arduino PG, Larda E, Chiecchio A, Gallesio G, et al. Tooth extractions in intravenous bisphosphonate-treated patients: a refined protocol. J Oral Maxillofac Surg. 2013;71:994-9.

24. Mozzati M, Arata V, Gallesio G. Tooth extraction in patients on zoledronic acid therapy. Oral Oncol. 2012;48:817-21.

25. Asaka T, Ohga N, Yamazaki Y, Sato J, Satoh C, Kitagawa Y. Platelet-rich fibrin may reduce the risk of delayed recovery in tooth-extracted patients undergoing oral bisphosphonate therapy: a trial study. Clin Oral Investig. 2017;21:2165-72.

26. Choukroun J, Diss A, Simonpieri A, Girard MO, Schoeffler C, Dohan SL, et al. Platelet-rich fibrin (PRF): A second-generation platelet concentrate. IV. Clinical effects on tissue healing. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006;101:e56-60.

27. Hawkins D, Abrahamse H. Effect of multiple exposures of low-level laser therapy on the cellular responses of wounded human skin fibroblasts. Photomed Laser Surg. 2006;24:705-14.

28. Kan B, Altay MA, Taşar F, Akova M. Low-level laser therapy supported teeth extractions of two patients receiving IV zolendronate. Lasers Med Sci. 2011;26:569-75.

29. Vescovi P, Meleti M, Merigo E, Manfredi M, Fornaini C, Guidotti R, et al. Case series of 589 tooth extractions in patients under bisphosphonates therapy. Proposal of a clinical protocol supported by Nd:YAG low-level laser therapy. Med Oral Patol Oral Cir Bucal. 2013;18:e680-5.

30. Vescovi P, Meleti M, Merigo E, Meleti M, Manfredi M, Fornaini C, et al. Tooth Extractions in High-Risk Patients Under Bisphosphonate Therapy and Previously Affected With Osteonecrosis of the Jaws: Surgical Protocol Supported by Low-Level Laser Therapy. J Craniofac Surg. 2015;26:696-9.

**Funding**

There is no funding for this study.

**Conflict of Interest**

None of the authors has any conflict of interest to declare.